In this issue of INFECTIOUS DISEASES IN CHILDREN Monthly News Wire:
FDA ADVISORY PANEL GIVES NASAL INFLUENZA VACCINE A SHOT
BETHESDA, Md. - The cold-adapted, intranasal influenza vaccine (CAIV) (FluMist,
MedImmune and Wyeth) took one step closer to approval when an FDA advisory
panel said that efficacy and safety data for healthy individuals aged 5
through 49 warranted approval of the product.
INFECTIOUS DISEASES IN CHILDREN Symposium West
Fifth Annual Meeting to be held May 31-June 1
Update your pediatric office practice at the Fifth Annual INFECTIOUS DISEASES
IN CHILDREN Symposium West taking place on May 31-June 1, 2003, at the
exquisite Fairmont San Francisco. Hear the latest updates covering topics on
smallpox vaccines, otitis media, hepatitis A, asthma, and more. Register by
April 30 and receive $45 off the regular rate of $390.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.